Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Novel Therapeutic Strategies for Lung Cancer in the Era of...
share announcement

Novel Therapeutic Strategies for Lung Cancer in the Era of Personalized Treatment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (10 September 2022) | Viewed by 8662

Special Issue Editors

Dr. Konstantinos Porpodis

E-Mail Website
Guest Editor
Department of Pulmonary Medicine, General Hospital of Thessaloniki 'Georgios Papanikolaou', Aristotle University of Thessaloniki, 57010 Exohi Thessaloniki, Greece
Interests: lung cancer; interventional pulmonology; chemotherapy and immunotherapy
Dr. Kelly Domvri

E-Mail Website1 Website2
Guest Editor
1. Department of Pathology, General Hospital of Thessaloniki 'Georgios Papanikolaou', Thessaloniki, Greece
2. Laboratory of Histology-Embryology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
Interests: asthma; lung cancer; biomarkers; airway remodeling
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Lung cancer still remains as the world's leading cause of cancer death. Clinical development of immune checkpoint inhibitors (ICIs) has dramatically changed the prognosis of patients with non-small cell lung cancer. Of note, for the first time in 30 years, immunotherapy has also shown a survival benefit in patients with small cell lung cancer. Despite these advantages, the identification of reliable biomarkers is critical in efforts to further identify a subset of patients that may benefit from immunotherapy. Moreover, a combination of ICIs with other treatments is now under investigation to extend their efficacy in lung cancer patients.

Thus, the aim of this Special Issue is to highlight recent studies on therapeutic strategies and biomarker evaluation in lung cancer.

Dr. Konstantinos Porpodis
Dr. Kelly Domvri
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung cancer
  • biomarkers
  • immunotherapy
  • targeted therapies
  • personalized treatment
  • treatment combinations

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 1220 KiB  
Article
External Validation of a Prognostic Score for Survival in Lung Carcinoids
by Marco Chiappetta, Diomira Tabacco, Carolina Sassorossi, Isabella Sperduti, Giacomo Cusumano, Alberto Terminella, Ludovic Fournel, Marco Alifano, Francesco Guerrera, Pier Luigi Filosso, Samanta Nicosia, Filippo Gallina, Francesco Facciolo, Stefano Margaritora and Filippo Lococo
Cancers 2022, 14(11), 2601; https://doi.org/10.3390/cancers14112601 - 25 May 2022
Cited by 1 | Viewed by 1529
Abstract
Background: A prognostic score including T-dimension, age, histology and lymph node ratio was previously proposed in absence of an external validation dataset. The aim of the current study was to validate the proposed prognostic score using an independent dataset. Methods: Data of patients [...] Read more.
Background: A prognostic score including T-dimension, age, histology and lymph node ratio was previously proposed in absence of an external validation dataset. The aim of the current study was to validate the proposed prognostic score using an independent dataset. Methods: Data of patients with lung carcinoids, who underwent surgical resection and lymphadenectomy in five institutions from 1 January 2005 to 31 December 2019, were retrospectively analyzed. Two risk groups were created based on the following data: age, histology, node ratio and pT for disease-free survival (DFS); age, sex, node ratio and pT for overall survival (OS). The previously proposed score was validated, identifying two groups of patients: a high risk (HRG) and low risk (LRG) group. Results: The final analysis was conducted on 283 patients. Regarding DFS, 230 (81.3%) patients were assigned to the LRG and 53 (18.7%) to the HRG. Considering OS, 268 (94.7%) were allocated in the LRG and 15 (5.3%) in the HRG. The 5-year DFS was 92.7% in the LRG vs. 67% in the HRG (p < 0.001) while the 5-year OS was 93.6% in the LRG vs. 86.2% in the HRG (p = 0.29) with clear curve separation. Conclusion: Our analysis confirmed the validity of the composite score for DFS in lung carcinoids. Regarding OS, statistical significance was not reached because of a low number of deaths and patients in the HRG. Full article
(This article belongs to the Special Issue Novel Therapeutic Strategies for Lung Cancer in the Era of Personalized Treatment)
►▼ Show Figures

Figure 1

25 pages, 4670 KiB  
Article
Aspirin-Triggered Resolvin D1 Reduces Chronic Dust-Induced Lung Pathology without Altering Susceptibility to Dust-Enhanced Carcinogenesis
by Edward C. Dominguez, Rattapol Phandthong, Matthew Nguyen, Arzu Ulu, Stephanie Guardado, Stefanie Sveiven, Prue Talbot and Tara M. Nordgren
Cancers 2022, 14(8), 1900; https://doi.org/10.3390/cancers14081900 - 9 Apr 2022
Cited by 5 | Viewed by 3111
Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide, with increased risk being associated with unresolved or chronic inflammation. Agricultural and livestock workers endure significant exposure to agricultural dusts on a routine basis; however, the chronic inflammatory and carcinogenic effects of these [...] Read more.
Lung cancer is the leading cause of cancer-related deaths worldwide, with increased risk being associated with unresolved or chronic inflammation. Agricultural and livestock workers endure significant exposure to agricultural dusts on a routine basis; however, the chronic inflammatory and carcinogenic effects of these dust exposure is unclear. We have developed a chronic dust exposure model of lung carcinogenesis in which mice were intranasally challenged three times a week for 24 weeks, using an aqueous dust extract (HDE) made from dust collected in swine confinement facilities. We also treated mice with the omega-3-fatty acid lipid mediator, aspirin-triggered resolvin D1 (AT-RvD1) to provide a novel therapeutic strategy for mitigating the inflammatory and carcinogenic effects of HDE. Exposure to HDE resulted in significant immune cell influx into the lungs, enhanced lung tumorigenesis, severe tissue pathogenesis, and a pro-inflammatory and carcinogenic gene signature, relative to saline-exposed mice. AT-RvD1 treatment mitigated the dust-induced inflammatory response but did not protect against HDE + NNK-enhanced tumorigenesis. Our data suggest that chronic HDE exposure induces a significant inflammatory and pro-carcinogenic response, whereas treatment with AT-RvD1 dampens the inflammatory responses, providing a strong argument for the therapeutic use of AT-RvD1 to mitigate chronic inflammation. Full article
(This article belongs to the Special Issue Novel Therapeutic Strategies for Lung Cancer in the Era of Personalized Treatment)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

17 pages, 674 KiB  
Review
Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy
by Melania Grottoli, Paolo Carrega, Lodovica Zullo, Chiara Dellepiane, Giovanni Rossi, Francesca Parisi, Giulia Barletta, Linda Zinoli, Simona Coco, Angela Alama, Silvia Marconi, Monica Parodi, Paola Orecchia, Sara Bassi, Massimo Vitale, Maria Cristina Mingari, Ulrich Pfeffer, Carlo Genova and Gabriella Pietra
Cancers 2022, 14(20), 5046; https://doi.org/10.3390/cancers14205046 - 14 Oct 2022
Cited by 9 | Viewed by 2614
Abstract
Immune checkpoint inhibitors (ICIs) immunotherapy has represented a breakthrough in cancer treatment. Clinical use of ICIs has shown an acceptable safety profile and promising antitumor activity. Nevertheless, some patients do not obtain clinical benefits after ICIs therapy. In order to improve and cure [...] Read more.
Immune checkpoint inhibitors (ICIs) immunotherapy has represented a breakthrough in cancer treatment. Clinical use of ICIs has shown an acceptable safety profile and promising antitumor activity. Nevertheless, some patients do not obtain clinical benefits after ICIs therapy. In order to improve and cure an increasing number of patients, the field has moved toward the discovery of new ICIs expressed by cells of innate immunity with an elevated inherent antitumor activity, such as natural killer cells. This review will focus on the recent findings concerning the role of classical and non-classical immune checkpoint molecules and receptors that regulate natural killer cell function, as potential targets, and their future clinical application. Full article
(This article belongs to the Special Issue Novel Therapeutic Strategies for Lung Cancer in the Era of Personalized Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop